By Denny Jacob
Gene therapy developer uniQure shares soared 46% in premarket trading after its treatment for Huntington's disease received breakthrough therapy designation from the Food and Drug Administration.
Shares were trading around $13.70. The stock has doubled over the last year.
The Netherlands-based company said the FDA's designation for AMT-130 is in addition to the regenerative medicine advanced therapy designation, orphan drug designation and fast track designation previously granted by the regulator.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 17, 2025 08:25 ET (12:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.